Takeda Announces Collaboration to Develop Reproducible, Non-Viral Gene Therapies

On February 23, Takeda and Code Biotherapeutics (Code Bio) jointly announced a collaboration and option agreement whereby Takeda will utilize Code Bio's proprietary 3DNA-targeted non-viral gene drug delivery platform to design and develop treatments for rare diseases Indications for gene therapy

Through the agreement, Takeda and Code Bio will design and develop a targeted gene therapy utilizing Code Bio's 3DNA platform for a rare disease program in the liver, plus additional research in a rare disease program in the central nervous system

Code Bio's targeted 3DNA non-viral gene drug delivery platform is designed to overcome key limitations of other gene drug delivery routes and fully unlock the potential of gene drugs

References:

[1] Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases.

(Original abridged)